Targeting the Wnt signaling pathway to treat Barrett's esophagus

Détails

ID Serval
serval:BIB_0DD73208EE60
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Targeting the Wnt signaling pathway to treat Barrett's esophagus
Périodique
Expert Opinion on Therapeutic Targets
Auteur(s)
Clement  G., Jablons  D. M., Benhattar  J.
ISSN
1744-7631 (Electronic)
Statut éditorial
Publié
Date de publication
2007
Volume
11
Numéro
3
Pages
375-389
Notes
PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review
Résumé
Barrett's esophagus (BE) is an acquired condition in which the normal squamous epithelium in the distal esophagus is replaced by a metaplastic columnar epithelium, as a complication of chronic gastroesophageal reflux. The clinical significance of this disease is its associated predisposition to esophageal adenocarcinoma (EAC). Recently, and similarly to other human malignancies, the Wnt signaling pathway and its key component beta-catenin have been implicated in the carcinogenesis of BE. Although mutations in adenomatous polyposis coli (APC) or beta-catenin are rare in EAC, alterations of upstream components, such as overexpression of Wnt2 ligand or downregulation of Wnt antagonists may play dominant roles in the activation of the Wnt pathway. Increasing evidence suggests that inhibiting the Wnt pathway may be a new targeted therapy for the treatment of cancers and could, therefore, be promising for the cure of EAC, which remains a highly lethal disease
Mots-clé
Adenocarcinoma/drug therapy/etiology/metabolism/Animals/Antineoplastic Agents/therapeutic use/Barrett Esophagus/complications/Esophageal Neoplasms/Humans/Wnt Proteins/antagonists & inhibitors
Pubmed
Web of science
Création de la notice
29/01/2008 19:34
Dernière modification de la notice
03/03/2018 13:40
Données d'usage